Trial reportInternational journal of clinical oncology2013
A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients.
Trial report in International journal of clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.Sao Paulo medical journal = Revista paulista de medicina · 2009Pooled it
- Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.Annals of oncology : official journal of the European Society for Medical Oncology · 2010Trial
- Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008Trial
- Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease.Journal of neuro-oncology · 2022Review
- Lapatinib? or Radiotherapy? In Cranial Metastasis of Breast Cancer.European journal of breast health · 2019Article
- Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review.Breast care (Basel, Switzerland) · 2017Review
- Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.Oncotarget · 2016Article
- Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel.Breast care (Basel, Switzerland) · 2016Article
- Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment.Radiation oncology journal · 2016Review
- Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer.The journal of breast health · 2015Article
- Breast cancer brain metastases: the last frontier.Experimental hematology & oncology · 2015Review
- Innovative therapeutic strategies in the treatment of brain metastases.International journal of molecular sciences · 2013Article
- Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation.Case reports in oncological medicine · 2013Article
- Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.Cancer management and research · 2010Article
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.Nature reviews. Cancer · 2009Review
- Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers.Journal of oncology · 2009Article
- New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.Nature clinical practice. Oncology · 2009Review
- Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer.South Asian journal of cancerArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is known that one third of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic breast cancer (MBC) treated with trastuzumab will develop brain metastases. As the development of brain metastases is fatal, controlling its progression is clinically meaningful. However, effective therapy for MBC patients with brain metastasis after cranial radiation is limited. The international clinical study in which six Japanese patients participated indicated the antitumor activity of lapatinib against brain metastases of HER2-overexpressing breast cancer.
methodsThe efficacy, safety, and pharmacokinetics of lapatinib 750 mg given twice daily to Japanese HER2-overexpressing MBC patients with brain metastases were assessed as part of the international clinical study.
resultsOf six Japanese patients treated in this study, two patients had shown volumetric reduction >20 % in their central nervous system (CNS), one of whom had >50 % reduction. Three patients, including two of these patients, had shown >20 % volumetric reduction in non-CNS lesions. Frequently reported adverse events were diarrhea and rash, all of which were controllable. The AUC0-12 of lapatinib on day 28 was 1.74 times higher than that on day 1.
conclusionThese results suggest that lapatinib monotherapy 750 mg given twice daily can exert some efficacy and has potential as a clinically meaningful treatment option for Japanese HER2-overexpressing breast cancer patients with brain metastases after cranial radiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.